Authors
Latest:
Bezuclastinib Demonstrates Improved Symptoms in Systemic MastocytosisMedian duration on bezuclastinib was 56 weeks vs 40 weeks for placebo in non-advanced systemic mastocytosis, the phase 2 Summit trial reported.
Latest:
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous RituximabRituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.
Latest:
ctDNA Positivity More Frequent Less Than 6 Months from Treatment in TNBCThe phase 3 ZEST trial discovered that, with low ctDNA at baseline, the recurrence-free interval is longer for patients with triple-negative breast cancer.
Latest:
Impact of Tobacco Cessation on the Development of Bladder CancerVikram Narayan, MD, details the little-known fact that tobacco cessation is a leading preventative strategy of bladder cancer recurrence.
Latest:
Sholl Examines Importance of Pathology in Cancer Care“You have to look at the cell-free DNA results with a grain of salt and with some degree of sophistication in terms of what you can act on as a predictive biomarker in the blood.”
Latest:
Expert Emphasizes Importance of Cancer Prevention and Screenings on World Cancer DayAn expert from Ochsner Health discusses the essential role positive lifestyle habits and regular screenings play in preventing cancer diagnoses.
Latest:
Adverse Effects Associated With JAK Inhibitors in MyelofibrosisNaveen Pemmaraju, MD, discusses adverse effects associated with JAK inhibitors in the treatment of myelofibrosis, and the Oncology Brothers recap the entire discussion.
Latest:
Phillip H. Kuo, MD, PhD, Assesses Use of 177Lu-PSMA-617 in a Multidisciplinary Setting for Pretreated mCRPCPhillip H. Kuo, MD, PhD, spoke about incorporating prostate-specific membrane antigen–PET imaging into multidisciplinary care for patients with metastatic castration-resistant prostate cancer.
Latest:
Unmet Needs and Future Directions in the Management of Multiple MyelomaExperts from Ochsner Health close out their panel on multiple myeloma management by identifying unmet needs and sharing excitement for future evolution in the treatment landscape.
Latest:
Prostate Cancer Screening – What Does the Evidence Tell Us?In May 2012, the United States Preventive Services Task Force (USPSTF) released a recommendation against prostate-specific antigen (PSA) screening for men. The justification for this recommendation was that large randomized trials demonstrated that PSA screening increased detection of prostate cancer, but there was "small to no reduction in prostate cancer-specific mortality."
Latest:
Novel Nanomedicine Development for GlioblastomaWe spoke with Dr. Priya Kumthekar and Dr. Alexander Stegh about their nucleic acid-based therapeutic development that targets glioblastoma.
Latest:
Treating AR-Indifferent Prostate CancerAhead of the ASCO-sponsored 2017 Genitourinary Cancers Symposium being held February 16th to February 18th in Orlando, Florida, we spoke with Dr. Ana Aparicio about the role of androgen receptors in prostate cancer.
Latest:
Molecular Characterizations of Diffuse Large B-Cell LymphomaWe spoke with Dr. Anas Younes about the molecular characteristics of diffuse large B-cell lymphoma.
Latest:
PTEN Mutation Status Potential Biomarker for Endometrial Cancer TherapiesLoss of function of the PTEN tumor suppressor gene leads to resistance to therapies targeting the Notch signaling pathway according to a mouse study presented at the 2016 Society of Gynecologic Oncology annual meeting, held in San Diego, March 19-22, 2016.
Latest:
The Re-emergence of Gemtuzumab Ozogamicin for AMLIn this interview with Jorge Cortes, MD, he discusses why gemtuzumab ozogamicin is experiencing a comeback for the treatment of patients with acute myeloid leukemia.
Latest:
IMDC Prognostic Category May Predict Treatment Course for Metastatic RCC PatientsA recent study published in European Urology suggests that patterns of treatment failure might help to predict what the next treatment should be for patients with metastatic renal cell carcinoma.
Latest:
Nivolumab Offers Durable Responses in Relapsed/Refractory Hodgkin LymphomaA follow-up analysis of the CheckMate-205 clinical trial found that nivolumab was associated with durable response rates in adults with relapsed or refractory Hodgkin lymphoma after ASCT.
Latest:
Pembrolizumab Yields Strong Long-Term Survival in Advanced MelanomaIn this video we discuss 3-year overall survival data from the KEYNOTE-001 trial, which studied the anti–PD-1 antibody pembrolizumab in patients with advanced melanoma.
Latest:
Woman With a Polypoid Endometrial TumorA 52-year-old woman presents with a polypoid endometrial tumor. What is your diagnosis?
Latest:
ASCO: Presentation Preview on Immunotherapy Approaches for Urological CancersAs part of our coverage of the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, we discuss some of the immunotherapy treatment options for urological cancers.
Latest:
Novel Quadruplet Therapy Shows Promise in Multiple MyelomaIn this interview with Charlotte Pawlyn, MB, BChir, PhD, she discusses results of the Myeloma XI study, which tested a novel quadruplet therapy for patients with newly diagnosed multiple myeloma.
Latest:
Genomic Guided Therapy: Show Me the Data!I was recently asked to speak to an audience of nonmedical adult participants enrolled in a leadership program in St. Petersburg, Florida. Many of the attendees were lawyers, bankers, and other professionals, who were generally foreign to the world of genetic cancer research. I was specifically asked to discuss how Moffitt Cancer Center is working to fight cancer through personalized medicine.
Latest:
'That’s Just My Luck to Get This Lousy Doctor'He came to our large, urban teaching hospital in search of a cure for his stomach cancer. We met during the workup stage of his care while he was suffering from intractable nausea, yet we still needed test results before we would know what kind of treatment we could offer.
Latest:
Uncovering Mechanisms Associated With ADT Resistance in Prostate CancerIn this video, David Goodrich, PhD, of Roswell Park Cancer Institute in Buffalo, discusses treatment resistance and disease relapse in prostate cancer.
Latest:
Why Elephants Don't Get CancerIn 1992, I moved to the Washington DC area and attended a conference on new and projected trends in cancer care at the National Institutes of Health.
Latest:
Incorporating Precision Medicine Into the Treatment of NSCLCDr. Kim discusses why non-small cell lung cancer should be considered the paradigm for precision medicine, and how treatment of the disease has changed over the last decade.
